Evidence map›Paper›PMID 35211253›Full record

Trial reportJournal of healthcare engineering2022

Efficacy and Safety of Temozolomide Combined with Radiotherapy in the Treatment of Malignant Glioma.

Shoufeng Wei, Junde Li

RetractedOpen access · hybridAbstract readRandomized Controlled TrialRetracted Publication
In one paragraph

Trial report in Journal of healthcare engineering, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 2 institutions in 1 country.

Shoufeng WeiDepartment of Neurosurgery, Zibo Central Hospital, Zibo 255000, Shandong, China.ORCID 0000-0002-8923-4975
Junde LiDepartment of Neurosurgery, Zibo Maternal and Child Health Care Hospital, Zibo 255100, Shandong, China.ORCID 0000-0002-0039-9731
Central Hospital of Zibo · CNThe Fourth People's Hospital of Zibo City · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

MG is a clinical common intracranial tumor, with the characteristics of strong invasion. In our study, we aim to explore the efficacy and safety of temozolomide combined with radiotherapy in the treatment of malignant glioma (MG) and its influence on postoperative complications and survival rate of patients. 120 MG patients admitted to our hospital (January 2019-January 2020) were chosen as the research objects and were randomly divided into group A (

Indexed as

GliomaQuality of LifeAntineoplastic Agents, AlkylatingHumansPostoperative ComplicationsTemozolomideTreatment OutcomeAntineoplastic Agents, AlkylatingTemozolomide

Identifiers

PMID35211253
PMCPMC8863446
OpenAlexW4214496463

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.